Charles Schwab
TCON

Charles Schwab’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Charles Schwab’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,132
Closed -$6.59K – 3649
2023
Q2 		$6.59K Hold
1,132
– – ﹤0.01% 3603
2023
Q1 		$42.8K Buy
+1,132
New +$37.1K ﹤0.01% 3375

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Charles Schwab's TCON Position: Q3 2023 in Review

Charles Schwab sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q3 2023, closing a stake of 1,132 shares — an estimated $6.59K sold.

Charles Schwab first reported a position in TCON in Q1 2023 and held it in 2 quarters. The position peaked at $42.8K in Q1 2023. 21 funds tracked by Wall St. Rank hold TCON as of Q3 2023.

  • Charles Schwab reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Charles Schwab sold 1,132 TRACON Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $6.59K.
  • Charles Schwab first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Charles Schwab's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $42.8K in Q1 2023.
  • 21 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.